Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#1 / 100 Total
LAB - Standard BioTools Inc - Stock Price Chart
TickerLAB [NASD]
CompanyStandard BioTools Inc
CountryUSA
IndustryDiagnostics & Research
Market Cap984.44MEPS (ttm)-1.00
P/E-EPS this Y64.54%
Forward P/E-EPS next Y47.00%
PEG-EPS past 5Y8.72%
P/S7.77EPS next 5Y-
P/B1.69EPS Q/Q-24.79%
Dividend-Sales Q/Q81.30%
Insider Own3.26%Inst Own69.17%
Insider Trans14.73%Inst Trans-1.58%
Short Float3.08%EarningsMay 08/a
Analyst Recom1.00Target Price3.58
Avg Volume2.50M52W Range1.57 - 3.16
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Casdin Partners Master Fund, LDirectorMay 17 '24Buy2.56352,072902,04445,375,821May 17 08:11 PM
Casdin Partners Master Fund, LDirectorMay 16 '24Buy2.54500,0001,270,95045,023,749May 17 08:11 PM
Black Jeffrey G.SVP & Chief Financial OfficerMay 15 '24Option Exercise0.0052,6310138,615May 16 09:07 PM
Casdin Partners Master Fund, LDirectorMay 15 '24Buy2.57500,0001,282,55044,523,749May 17 08:11 PM
Kim Hanjoon AlexChief Operating OfficerApr 04 '24Option Exercise0.0070,1830140,366Apr 05 06:58 PM
VERU - Veru Inc - Stock Price Chart
TickerVERU [NASD]
CompanyVeru Inc
CountryUSA
IndustryBiotechnology
Market Cap193.22MEPS (ttm)-0.34
P/E-EPS this Y75.82%
Forward P/E-EPS next Y-13.53%
PEG-EPS past 5Y-19.79%
P/S14.33EPS next 5Y-
P/B4.27EPS Q/Q85.73%
Dividend-Sales Q/Q-37.21%
Insider Own14.11%Inst Own37.61%
Insider Trans-0.79%Inst Trans-6.50%
Short Float9.73%EarningsMay 08/b
Analyst Recom1.60Target Price3.44
Avg Volume2.48M52W Range0.36 - 1.92
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company's drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STEINER MITCHELL SHUSTERPresident and CEOMay 17 '24Sale1.3228,06636,9887,012,892May 17 07:41 PM
STEINER MITCHELL SHUSTERPresident and CEOMay 16 '24Sale1.4159,78884,1287,040,958May 17 07:41 PM
FISCH HARRYChief Corporate OfficerMay 15 '24Buy1.496,7119,999770,736May 17 07:46 PM
STEINER MITCHELL SHUSTERPresident and CEOMay 15 '24Sale1.5084,021125,8137,100,746May 17 07:41 PM
SRE - Sempra - Stock Price Chart
TickerSRE [NYSE, S&P 500]
CompanySempra
CountryUSA
IndustryUtilities - Diversified
Market Cap49.47BEPS (ttm)4.52
P/E17.31EPS this Y4.38%
Forward P/E15.15EPS next Y7.20%
PEG2.93EPS past 5Y22.84%
P/S3.64EPS next 5Y5.90%
P/B1.75EPS Q/Q-17.74%
Dividend3.22%Sales Q/Q-45.60%
Insider Own0.04%Inst Own90.34%
Insider Trans-39.89%Inst Trans-0.24%
Short Float1.82%EarningsMay 07/b
Analyst Recom1.59Target Price84.03
Avg Volume3.22M52W Range63.75 - 78.40
Sempra is an energy-service holding company, which engages in the development and operation of energy infrastructure, and provision of electric and gas services. It operates through the following segments: Sempra California, Sempra Texas Utilities, Sempra Infrastructure, and All Other. The Sempra California segment offers natural gas and electric service to Southern California and part of central California through Sempra's wholly owned subsidiaries, SDG&E and SoCalGas. The Sempra Texas Utilities holds investment in Oncor Holdings. The Sempra Infrastructure includes the operating companies of subsidiary, SI Partners, as well as a holding company and certain services companies. The company was founded on October 11, 1996, and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARK RICHARD JDirectorMay 17 '24Buy77.971,925150,0925,420May 17 07:22 PM
BIRD JUSTIN CHRISTOPHERExecutive Vice PresidentMar 08 '24Sale70.606,278443,22713,434Mar 08 07:40 PM
Sedgwick Karen LExecutive VP and CFOMar 08 '24Sale70.593,624255,81839,400Mar 08 07:40 PM
DAY DIANA LChief Legal CounselMar 08 '24Sale70.623,406240,53214,739Mar 08 07:39 PM
Sedgwick Karen LExecutive VP and CFOMar 07 '24Sale71.215,158367,30143,024Mar 08 07:40 PM
AVD - American Vanguard Corp. - Stock Price Chart
TickerAVD [NYSE, RUT]
CompanyAmerican Vanguard Corp.
CountryUSA
IndustryAgricultural Inputs
Market Cap254.62MEPS (ttm)0.25
P/E36.52EPS this Y125.00%
Forward P/E9.73EPS next Y59.83%
PEG-EPS past 5Y-20.02%
P/S0.43EPS next 5Y-1.00%
P/B0.71EPS Q/Q-16.36%
Dividend1.32%Sales Q/Q8.21%
Insider Own10.21%Inst Own80.90%
Insider Trans3.06%Inst Trans-4.28%
Short Float3.76%EarningsMay 09/a
Analyst Recom1.00Target Price18.00
Avg Volume203.83K52W Range8.41 - 18.38
American Vanguard Corp. is a holding company which engages in the development and marketing of specialty and agricultural products for crop protection and management, turf and ornamentals management, public and animal health. It also acquires and licenses both new and well-established product lines that serve numerous market niches. The company was founded by Herbert A. Kraft and Glenn A. Wintemute in January 1969 and is headquartered in Newport Beach, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Trogele UlrichSee RemarksMay 16 '24Buy8.7518,200159,318209,876May 17 07:00 PM
ROSENBLOOM KEITH MDirectorMay 15 '24Buy8.8840,000355,2001,014,155May 17 10:28 AM
Macicek Steven DDirectorMay 15 '24Buy9.018,50076,62410,044May 17 06:26 AM
Trogele UlrichSee RemarksDec 14 '23Buy10.725,00053,625191,676Dec 14 08:30 PM
Trogele UlrichSee RemarksDec 11 '23Buy10.052,48825,004186,676Dec 12 02:13 PM
SCLX - Scilex Holding Company - Stock Price Chart
TickerSCLX [NASD]
CompanyScilex Holding Company
CountryUSA
IndustryDrug Manufacturers - General
Market Cap163.07MEPS (ttm)-0.89
P/E-EPS this Y49.61%
Forward P/E-EPS next Y37.21%
PEG-EPS past 5Y-
P/S3.47EPS next 5Y-
P/B-EPS Q/Q-9.63%
Dividend-Sales Q/Q2.85%
Insider Own38.07%Inst Own15.96%
Insider Trans0.38%Inst Trans-8.47%
Short Float7.68%Earnings-
Analyst Recom1.00Target Price6.25
Avg Volume1.03M52W Range0.73 - 8.37
May-14-24 09:00AM Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's intent to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba (GlobeNewswire)
08:53AM SCLX Stock Earnings: Scilex Holding Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-13-24 09:00AM Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock (GlobeNewswire) +7.98%
Apr-25-24 04:01PM Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering (GlobeNewswire)
Apr-24-24 08:00AM Scilex Holding Company Announces $15 Million Registered Direct Offering (GlobeNewswire) -12.97%
Apr-16-24 09:00AM Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses (GlobeNewswire) -9.38%
Apr-09-24 09:00AM Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido and ELYXYB for Commercially Insured Patients and the addition of ELYXYB to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool (GlobeNewswire)
Mar-27-24 09:00AM Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend (GlobeNewswire) +6.62%
Mar-21-24 09:30AM Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients (GlobeNewswire)
Mar-20-24 11:00AM Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed (GlobeNewswire)
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHAH JAISIMSee RemarksMay 17 '24Buy0.9256,93952,099155,882May 17 05:36 PM
Chun JayDirectorMay 17 '24Buy0.9057,50051,641102,500May 17 06:41 PM
Ji HenryExecutive ChairpersonMay 17 '24Buy0.8850,00043,98550,070May 17 06:42 PM
Ma Stephen HoiChief Financial OfficerMay 17 '24Buy0.8814,14012,44314,140May 17 04:29 PM
SHAH JAISIMSee RemarksMay 16 '24Buy0.8483,06169,84698,943May 17 05:36 PM
PDYN - Palladyne AI Corp. - Stock Price Chart
TickerPDYN [NASD]
CompanyPalladyne AI Corp.
CountryUSA
IndustrySoftware - Infrastructure
Market Cap42.56MEPS (ttm)-3.94
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S5.84EPS next 5Y-
P/B1.24EPS Q/Q-98.79%
Dividend-Sales Q/Q49.87%
Insider Own45.59%Inst Own6.99%
Insider Trans0.67%Inst Trans185.68%
Short Float3.19%EarningsNov 14/a
Analyst Recom3.00Target Price1.00
Avg Volume1.02M52W Range0.40 - 3.25
May-13-24 08:52AM PDYN Stock Earnings: Palladyne AI Misses Revenue for Q1 2024 (InvestorPlace)
Apr-16-24 07:52AM PDYN Stock Earnings: Palladyne AI Misses EPS, Misses Revenue for Q2 2023 (InvestorPlace) -8.47%
Apr-08-24 09:00AM Palladyne AI Ticker Symbol now PDYN (Business Wire) +6.91%
Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its mobile robotic systems include the Guardian S, Guardian GT, Guardian XO, and Guardian XT. The company was founded in 2015 and is headquartered in Salt Lake City, UT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WEIBLING DENNIS MDirectorMay 15 '24Buy1.3655,00074,596229,831May 17 05:57 PM
Wolff Benjamin GPRESIDENT & CEOMay 15 '24Buy1.352,6553,5911,259,618May 17 05:53 PM
Wolff Benjamin GPRESIDENT & CEOMay 14 '24Buy1.3112,00015,7311,256,963May 15 05:56 PM
Wolff Benjamin GPRESIDENT & CEOMay 13 '24Buy1.3511,17615,0641,244,963May 15 05:56 PM
EHAB - Enhabit Inc - Stock Price Chart
TickerEHAB [NYSE, RUT]
CompanyEnhabit Inc
CountryUSA
IndustryMedical Care Facilities
Market Cap413.82MEPS (ttm)-1.67
P/E-EPS this Y22.48%
Forward P/E23.70EPS next Y29.18%
PEG-EPS past 5Y-
P/S0.40EPS next 5Y-
P/B0.62EPS Q/Q-92.58%
Dividend-Sales Q/Q-1.02%
Insider Own12.25%Inst Own97.02%
Insider Trans0.35%Inst Trans-
Short Float6.95%EarningsMay 08/a
Analyst Recom3.12Target Price9.32
Avg Volume649.90K52W Range7.12 - 14.59
Enhabit, Inc. functions as an investment holding company. It operates under the Home Health and Hospice segments. The Home Health segment provides home health services via home nursing services to adult patients in need of care. The Hospice segment offers hospice agencies. The company was founded in 2014 and is headquartered in Dallas, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bolton JeffreyDirectorMay 17 '24Buy8.3310,00083,30052,299May 17 05:57 PM
Hoeflinger ErinDirectorMay 14 '24Buy9.002,00018,00030,399May 15 06:29 PM
Bolton JeffreyDirectorMay 10 '24Buy8.2410,00082,40042,299May 10 05:27 PM
Langham Ronald Leroy JREVP Clinical Excel. & StrategyMar 01 '24Sale8.816345,58657,164Mar 05 05:48 PM
Bolton JeffreyDirectorMay 26 '23Buy11.612,00023,22019,597May 31 08:17 PM
RIG - Transocean Ltd - Stock Price Chart
TickerRIG [NYSE]
CompanyTransocean Ltd
CountrySwitzerland
IndustryOil & Gas Drilling
Market Cap4.94BEPS (ttm)-0.53
P/E-EPS this Y93.32%
Forward P/E17.39EPS next Y640.84%
PEG-EPS past 5Y21.86%
P/S1.68EPS next 5Y-
P/B0.47EPS Q/Q116.06%
Dividend-Sales Q/Q17.57%
Insider Own11.85%Inst Own68.10%
Insider Trans8.98%Inst Trans2.90%
Short Float17.72%EarningsApr 29/a
Analyst Recom2.40Target Price7.02
Avg Volume18.50M52W Range4.45 - 8.88
Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PerestroikaDirectorMay 15 '24Buy6.012,000,00012,020,00087,574,894May 17 05:43 PM
Mohn Frederik WilhelmDirectorMay 15 '24Buy6.012,000,00012,020,00087,574,894May 17 05:42 PM
Perestroika (Cyprus) LtdDirectorMay 15 '24Buy6.012,000,00012,020,00087,574,894May 17 05:44 PM
THIGPEN JEREMY DCEOMar 01 '24Option Exercise5.09941,1924,790,6675,551,127Mar 05 07:10 PM
Mey Mark-Anthony LovellEVP & CFOMar 01 '24Option Exercise5.09325,8051,658,3471,724,606Mar 05 07:12 PM
OPK - Opko Health Inc - Stock Price Chart
TickerOPK [NASD, RUT]
CompanyOpko Health Inc
CountryUSA
IndustryDiagnostics & Research
Market Cap920.03MEPS (ttm)-0.34
P/E-EPS this Y-49.33%
Forward P/E-EPS next Y27.68%
PEG-EPS past 5Y1.56%
P/S1.15EPS next 5Y12.00%
P/B0.73EPS Q/Q-376.54%
Dividend-Sales Q/Q-26.89%
Insider Own52.98%Inst Own25.80%
Insider Trans2.88%Inst Trans-3.05%
Short Float26.42%EarningsMay 07/a
Analyst Recom1.00Target Price4.25
Avg Volume8.38M52W Range0.85 - 2.24
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FROST PHILLIP MD ET ALCEO & ChairmanMay 17 '24Buy1.29163,997211,195211,132,222May 17 05:31 PM
FROST PHILLIP MD ET ALCEO & ChairmanMar 18 '24Buy0.87500,000437,100210,968,225Mar 18 04:45 PM
FROST PHILLIP MD ET ALCEO & ChairmanMar 14 '24Buy0.89500,000444,300210,468,225Mar 14 05:00 PM
FROST PHILLIP MD ET ALCEO & ChairmanMar 13 '24Buy0.93500,000463,750209,968,225Mar 13 04:44 PM
FROST PHILLIP MD ET ALCEO & ChairmanMar 12 '24Buy0.93600,000559,380209,468,225Mar 12 05:27 PM
RKT - Rocket Companies Inc - Stock Price Chart
TickerRKT [NYSE]
CompanyRocket Companies Inc
CountryUSA
IndustryMortgage Finance
Market Cap1.97BEPS (ttm)0.12
P/E116.02EPS this Y522.22%
Forward P/E25.43EPS next Y87.85%
PEG-EPS past 5Y-
P/S0.51EPS next 5Y-
P/B3.01EPS Q/Q171.29%
Dividend-Sales Q/Q30.04%
Insider Own12.20%Inst Own63.95%
Insider Trans0.07%Inst Trans-0.23%
Short Float15.11%EarningsMay 02/a
Analyst Recom3.60Target Price11.63
Avg Volume2.63M52W Range7.17 - 15.60
Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rizik MatthewDirectorMay 17 '24Buy13.8525346700,613May 17 05:17 PM
Rizik MatthewDirectorMay 16 '24Buy14.013044,259700,588May 17 05:17 PM
Rizik MatthewDirectorMay 15 '24Buy14.503004,350700,284May 15 05:27 PM
Rizik MatthewDirectorMay 10 '24Buy13.683114,254699,984May 10 05:23 PM
Rizik MatthewDirectorMay 09 '24Buy13.8630416699,673May 10 05:23 PM
12345678910